Returning guest, Dr. Gregg Sylvester, Chief Medical Officer at Seqirus discusses real-world evidence on the company’s MF59® Adjuvanted, Trivalent Influenza Vaccine that was recently published in the peer-reviewed medical journal “Vaccines”. The study demonstrated that this vaccine was more effective than a standard-dose non-adjuvanted trivalent seasonal vaccine in preventing influenza-related medical office visits and hospitalizations/ER visits in adults 65+ during the 2017/18 U.S. influenza season.
Dr. Gregg Sylvester serves as the Chief Medical Officer of Seqirus. He has been with the company since 2016, previously serving as Vice President of Medical Affairs. Prior to this, Dr. Sylvester held a variety of senior management positions, including Global Medical Lead for Pfizer’s pediatric pneumococcal vaccine and Worldwide Medical Lead for Merck’s HPV vaccine and Cabinet Secretary for Delaware’s Health & Social Services. Dr. Sylvester is a preventive medicine expert with a passion for disease prevention and health promotion on a local, statewide, and global basis. He has focused his career on developing sound health policy, implementing innovative public health programs and accelerating vaccine use worldwide.